Search Articles

View query in Help articles search

Search Results (1 to 2 of 2 Results)

Download search results: CSV END BibTex RIS


Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol

Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol

CI: confidence interval; CRE: clinical response evaluation; n CRT: neoadjuvant chemoradiotherapy; N: number of patients; TRG: tumor regression grade, as measured by the modified TRG system of Chirieac. Of the 45 patients who will undergo a postponed resection following CRE-II, 15 patients are expected to have a pathologically incomplete response (at least TRG2). The clinical response evaluation will consist of different diagnostic modalities.

Bo Jan Noordman, Joel Shapiro, Manon CW Spaander, Kausilia K Krishnadath, Hanneke WM van Laarhoven, Mark I van Berge Henegouwen, Grard AP Nieuwenhuijzen, Richard van Hillegersberg, Meindert N Sosef, Ewout W Steyerberg, Bas PL Wijnhoven, J Jan B van Lanschot

JMIR Res Protoc 2015;4(2):e79